Brief: VBL Therapeutics Provides Update On Phase 3 Study Of VB-111 In Ovarian Cancer

Notable Labs

15/06/2021 12:17

June 15 (Reuters) - Vascular Biogenics Ltd  VBLT.O :
    * VBL THERAPEUTICS PROVIDES UPDATE ON OVAL, A PHASE 3
REGISTRATION
ENABLING STUDY OF VB-111 IN OVARIAN CANCER
    * VBL THERAPEUTICS - WAS NOTIFIED BY FDA THAT CLEARANCE OF
NEW
VB-111 BATCHES FOR USE IN U.S. IS CURRENTLY PENDING COMPLETION
OF REVIEW BY CMC GROUP
    * VBL THERAPEUTICS - UNTIL NEW BATCHES ARE CLEARED, COMPANY
ANTICIPATES A TEMPORARY SHORTAGE OF STUDY DRUG SUPPLY FOR U.S.
    * VBL THERAPEUTICS - ACCORDINGLY, RECRUITMENT OF NEW
PATIENTS IN
U.S. WILL BE TEMPORARILY PAUSED
    * VBL THERAPEUTICS - TREATMENT WILL CONTINUE AS USUAL FOR
ALL U.S.
PATIENTS CURRENTLY ENROLLED

Source text for Eikon:  ID:nGNX5PKH1x 
Further company coverage:  VBLT.O 

 ((Reuters.Briefs@thomsonreuters.com;))